Verano Holdings (VRNO) Shares Outstanding (2021 - 2026)
Verano Holdings (VRNO) posted quarterly Shares Outstanding (Entity) of $364.3 million for Q1 2026, up 1.29% year-over-year from $359.7 million in Q1 2025, and little changed quarter-over-quarter from $363.2 million in Q4 2025.
Verano Holdings (VRNO) Shares Outstanding (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has reported Shares Outstanding (Entity) for 6 consecutive years, with $364.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 1.29% year-over-year to $364.3 million; the TTM figure through Mar 2026 stood at $364.3 million (up 1.29% YoY), while the FY2025 annual figure was $363.2 million, up 1.25% from the prior year.
- Shares Outstanding (Entity) was little changed at $364.3 million in Q1 2026 per VRNO's latest filing, from $363.2 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $364.3 million in Q1 2026 and bottomed at $313.7 million in Q2 2022.
- Historically, Shares Outstanding (Entity) has averaged $346.8 million across 5 years, with a median of $344.2 million in 2024.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) advanced 9.44% — and 2024, when it rose 0.54%.
- Verano Holdings' Shares Outstanding (Entity) stood at $340.0 million in 2022, then increased by 1.2% to $344.1 million in 2023, then grew by 4.26% to $358.7 million in 2024, then increased by 1.25% to $363.2 million in 2025, then rose by 0.3% to $364.3 million in 2026.
- Business Quant data shows VRNO's Shares Outstanding (Entity) at $364.3 million in Q1 2026, $363.2 million in Q4 2025, and $361.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | 4.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 1.17 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 417.60 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 1.58 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 42.60 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 1.16 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 101.00 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 499.50 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | 832.44 Mn |
| 10 | Verano Holdings | 442.47 Mn | 357.28 Mn | 99.70 Mn | 73.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 73.01 Mn |
| Mar 31, 2026 | 363.37 Mn |
| Dec 31, 2025 | 360.91 Mn |
| Sep 30, 2025 | 361.79 Mn |
| Jun 30, 2025 | 360.37 Mn |
| Mar 31, 2025 | 359.15 Mn |
| Dec 31, 2024 | 349.58 Mn |
| Sep 30, 2024 | 351.17 Mn |
| Jun 30, 2024 | 345.02 Mn |
| Mar 31, 2024 | 344.08 Mn |
| Dec 31, 2023 | 342.77 Mn |
| Sep 30, 2023 | 343.43 Mn |
| Jun 30, 2023 | 342.53 Mn |
| Mar 31, 2023 | 341.48 Mn |
| Dec 31, 2022 | 331.41 Mn |
| Sep 30, 2022 | 332.87 Mn |
| Jun 30, 2022 | 328.52 Mn |
| Mar 31, 2022 | 326.29 Mn |
| Dec 31, 2021 | 290.44 Mn |
| Sep 30, 2021 | 313.67 Mn |